Sutro Biopharma (STRO) Interest & Investment Income (2017 - 2025)

Sutro Biopharma has disclosed Interest & Investment Income across 9 years of filings, most recently posting $12.3 million for Q4 2025.

• Interest & Investment Income for Q4 2025 came in at $12.3 million, up 253.28% year-over-year; the trailing twelve-month figure through Dec 2025 was $16.5 million (up 330.91% YoY), and the FY2025 annual result was $9.3 million, down 50.38% from the prior year.
• Interest & Investment Income came in at $12.3 million for Q4 2025 at Sutro Biopharma, up from $2.0 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $12.3 million in Q4 2025 to a low of -$8.0 million in Q4 2024.
• The 5-year median for Interest & Investment Income is -$625500.0 (2022), against an average of $10600.0.
• Across the five-year window, Interest & Investment Income sank 2657.8% in 2022 and surged 277.98% in 2024, its largest moves.
• Sutro Biopharma's Interest & Investment Income stood at -$3.6 million in 2021, then soared by 158.82% to $2.1 million in 2022, then soared by 114.19% to $4.6 million in 2023, then slumped by 276.39% to -$8.0 million in 2024, then soared by 253.28% to $12.3 million in 2025.
• The last three Interest & Investment Income figures came in at $12.3 million (Q4 2025), $2.0 million (Q3 2025), and -$1.0 million (Q2 2025), per Business Quant data.